Evidence map›Paper›PMID 31365765›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2020

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

J A Davidson, C Desouza, V Fonseca, J P Frias, L Van Gaal, F Giorgino, J Chao, T A Dex, M Roberts, A Saremi and 1 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02058147. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02058147 phase3completed

A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Ran2014Enrolled1,170Registered outcomes15Posted comparisons15ConditionsType 2 DiabetesArmsInsulin glargine (HOE901), Insulin glargine/lixisenatide Fixed Ratio Combination, Lixisenatide (AVE0010), Metformin
PMID 27527848other papers from this trial
Open the trial in the graph
NCT02058160 phase3completed

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Ran2014Enrolled736Registered outcomes15Posted comparisons8ConditionsType 2 DiabetesArmsInsulin glargine (HOE901), Insulin glargine/lixisenatide (HOE901/AVE0010), Metformin (Background drug)
PMID 27650977other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

J A DavidsonTouchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-8542-3528
C DesouzaUniversity of Nebraska Medical Center, Omaha, NE, USA.
V FonsecaTulane University Health Sciences Center, New Orleans, LA, USA.
J P FriasNational Research Institute, Los Angeles, CA, USA.
L Van GaalAntwerp University Hospital, Edegem-Antwerp, Belgium.
F GiorginoUniversity of Bari Aldo Moro, Bari, Italy.
J ChaoXinyi, Inc., Bridgewater, NJ, USA.
T A DexSanofi US, Inc., Bridgewater, NJ, USA.
M RobertsSanofi US, Inc., Bridgewater, NJ, USA.
A SaremiSanofi US, Inc., Bridgewater, NJ, USA.
L A LeiterLi Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-1040-6229
Sanofi (United States) · USAntwerp University Hospital · BEBridgewater College · USNational Research Institute · USSt. Michael's Hospital · CAThe University of Texas Southwestern Medical Center · USTulane University · USUniversity of Bari Aldo Moro · ITUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsBoth fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA

methodsIn this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated to compare the relationship between achievement of society-recommended FPG and/or PPG targets and efficacy (HbA

resultsAcross treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA

conclusionInsulin glargine and lixisenatide as a fixed-ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA

Indexed as

Postprandial PeriodAgedBlood GlucoseDiabetes Mellitus, Type 2Drug CombinationsFastingFemaleGlucagon-Like Peptide-2 ReceptorGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsInsulin GlargineMaleMiddle AgedPeptidesBlood GlucoseDrug CombinationsGlucagon-Like Peptide-2 ReceptorGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin GlarginelixisenatidePeptides

Identifiers

PMID31365765
PMCPMC7003844
OpenAlexW2965609155

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.